| 1022 |
Effects of Intensive Blood Pressure Lowering on Brain Swelling in Thrombolyzed Acute Ischemic Stroke: The ENCHANTED Results
|
2025-04-30 |
844 |
| 1021 |
Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trial
|
2025-04-30 |
742 |
| 1020 |
Acute Blood Pressure Lowering and Risk of Ischemic Lesions on MRI After Intracerebral Hemorrhage
|
2025-04-30 |
821 |
| 1019 |
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
|
2025-03-31 |
777 |
| 1018 |
Thrombectomy With Low ASPECTS: The Roles of Infarct Volume and Postacute Neurological Status
|
2025-03-31 |
921 |
| 1017 |
Optimal Duration of Dual Antiplatelet Therapy After Carotid Artery Stenting: A Nationwide Cohort Study
|
2025-03-31 |
1,228 |
| 1016 |
Early Versus Delayed Antihypertensive Treatment After Acute Ischemic Stroke by Hypertension History (CATIS-2 Trial)
|
2025-02-27 |
801 |
| 1015 |
Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion (ESCAPE-MeVO Trial)
|
2025-02-27 |
914 |
| 1014 |
Endovascular Treatment for Stroke Due to Occlusion of Medium or Distal Vessels
|
2025-02-27 |
828 |
| 1013 |
Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysis
|
2025-01-31 |
764 |
| 1012 |
Surgical Management of Intracerebral Hemorrhage: New Light on the Horizon?
|
2025-01-31 |
1,447 |
| 1011 |
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
|
2025-01-31 |
799 |
| 1010 |
Large-Core Ischemic Stroke Endovascular Treatment: A Science Advisory From the American Heart Association
|
2024-12-31 |
1,128 |
| 1009 |
Effect of IV Thrombolysis With Alteplase in Patients With Vessel Occlusion in the WAKE-UP Trial
|
2024-12-31 |
763 |
| 1008 |
Liberal or Restrictive Transfusion Strategy in Aneurysmal Subarachnoid Hemorrhage
|
2024-12-31 |
668 |
HOME
LOGIN
